Skip to main content
SpringerLink
Log in

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to evaluate the effect of acetylsalicylic acid (ASA or aspirin) on the pharmacokinetics (PK) and pharmacodynamics (PD) of melagatran in healthy volunteers. Melagatran is the active form of the oral direct thrombin inhibitor, ximelagatran.

Methods

This was a double-blind, randomised, two-way, crossover study consisting of two treatment periods separated by a washout period of at least 2 weeks. Twelve subjects received, in a randomised order, either melagatran plus ASA in the first treatment period and melagatran plus placebo in the second treatment period or vice versa. Two single doses of ASA were given, first 450 mg on the day before (day 1) and then 150 mg just before administration of melagatran on day 2. Melagatran 4.12 mg was administered as an intravenous (i.v.) infusion over 4 h on day 2 of both treatment periods. Serial blood samples were collected over the course of the study for the determination of melagatran plasma concentration and coagulation analyses [activated partial thromboplastin time (APTT) and activated clotting time (ACT)]. Capillary bleeding time was measured before ASA/placebo on day 1 and before and after the start of the melagatran infusion on day 2.

Results

The plasma concentration of melagatran during the i.v. infusion was maintained at about 0.2 µmol/l, and ASA did not influence the PK parameters of melagatran. APTT and ACT increased with increasing melagatran plasma concentration, and the observed increases were similar whether melagatran was administered on top of ASA or placebo. Administration of ASA significantly prolonged the capillary bleeding time (by 41% relative to placebo). Melagatran also prolonged the bleeding time significantly (by 25% relative to placebo alone), but this prolongation was not significantly different from the observed prolongation when melagatran was administered on top of ASA (by 17% relative to ASA alone).

Conclusion

In young healthy volunteers, ASA had no effect on the PK or PD properties of melagatran at the studied dose. That the combination of ximelagatran with ASA may be used with acceptable safety must be verified in the relevant patient populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.

Similar content being viewed by others

References

  1. Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism, The Worcester DVT study. Arch Intern Med 151:933–938

    PubMed  Google Scholar 

  2. Nordström M, Lindblad B, Bergqvist D, Kjellström T (1992) A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med 232:155–160

    PubMed  Google Scholar 

  3. Rosendaal FR (1997) Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 78:1–6

    CAS  Google Scholar 

  4. Becker RC, Bovill EG, Seghatchian MJ, Samama MM (1998) Pathobiology of thrombin in acute coronary syndromes. Am Heart J 136:S19–S311

    CAS  PubMed  Google Scholar 

  5. Hirsh J (1991) Heparin. N Engl J Med 324:1565–1574

    Google Scholar 

  6. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324:1865–1875

    CAS  PubMed  Google Scholar 

  7. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287–1294

    CAS  PubMed  Google Scholar 

  8. Elg M, Gustafsson D, Deinum J (1997) The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 78:1286–1292

    CAS  PubMed  Google Scholar 

  9. Elg M, Gustafsson D, Carlsson S (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94:187–197

    Article  CAS  PubMed  Google Scholar 

  10. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C (1997) Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 78:1404–1407

    CAS  PubMed  Google Scholar 

  11. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110–118

    CAS  PubMed  Google Scholar 

  12. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E et al (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171–181

    Article  CAS  PubMed  Google Scholar 

  13. Mattsson C, Björkman J-A, Ulvinge J-C (1997) Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 11:121–128

    CAS  Google Scholar 

  14. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TGP (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31:345–351

    Article  PubMed  Google Scholar 

  15. Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D (2002) Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 87:300–305

    CAS  PubMed  Google Scholar 

  16. Carlsson S, Nilsson A, Börjesson I, Halvarsson M, Eriksson B, Mattsson C, Gustafsson D (1997) Melagatran, a novel low molecular weight thrombin inhibitor examined in several deep venous thrombosis models in the rat (abstract). Thromb Haemost 77[Suppl]:497

  17. Bredberg U, Eriksson UG, Taure K, Johansson L, Frison L, Gustafsson D (1999) Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers, following intravenous, subcutaneous and oral administration. Blood 94[Suppl 1]:28a

  18. Eriksson UG, Johansson L, Taure K, Frison L, Bredberg U, Gustafsson D (2000) Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95 in healthy male subjects. Haemostasis 30[Suppl 1]:164

  19. Eriksson UG, Liljenvald AC, Fager G, Thuresson A, Gabrielsson M (2000) The pharmacokinetics, metabolism and elimination of H 376/95, a novel, direct thrombin inhibitor, in healthy male subjects, after oral and intravenous administration. Pharmacotherapy 20:1264

    Google Scholar 

  20. Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip and knee replacement. METHRO I. Thromb Haemost 87:231–237

    CAS  PubMed  Google Scholar 

  21. Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, Sjöstedt Å, Folestad A, Arfwidsson A-C, Sareyko Elvander C, Frison L (2002) Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement. Results from phase II studies. Thromb Res 105:1–8

    Article  Google Scholar 

  22. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M (1999) Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 81:358–363

    CAS  PubMed  Google Scholar 

  23. Eriksson H, Wåhlander K, Gustafsson D, Welin L, Frison L, Schulman S for the THRIVE I Investigators (2003) A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. THRIVE I. J Thromb Haemost 1:41–47

    Article  Google Scholar 

  24. Wåhlander K, Lapidus L, Olsson C-G, Thuresson A, Eriksson UG, Larson G, Eriksson H (2002) Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107:93–99

    Article  PubMed  Google Scholar 

  25. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J et al (2002) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 161:2215–2221

    Article  Google Scholar 

  26. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR et al (2002) Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 137:648–655

    CAS  PubMed  Google Scholar 

  27. Lewis HD Jr, Davies JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of ASA against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 309:396–403

    PubMed  Google Scholar 

  28. Numano F, Kishi Y, Ashikaga T, Hata A, Makita T, Watanabe R (1995) What effect does controlling platelets have on atherosclerosis? Ann N Y Acad Sci 748:383–392

    Google Scholar 

  29. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1–13

    Article  CAS  PubMed  Google Scholar 

  30. Ridker PM, O'Donnell CJ, Hennekens CH (1995) Direct comparison of aspirin plus hirudin, aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: rationale and design of the first American Study of Infarct Survival (ASIS-1). J Thromb Thrombolysis 1:119–124

    PubMed  Google Scholar 

  31. Hart RG, Benavente O, Pearce LA (1999) Increased risk of intracranial hemorrhage when ASA is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 9:215–217

    Article  CAS  PubMed  Google Scholar 

  32. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A (2002) Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B 766:47–55

    Article  CAS  Google Scholar 

  33. Chan TY (1995) Adverse reactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 29:1274–1283

    CAS  PubMed  Google Scholar 

  34. Needs CJ, Brooks PM (1985) Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 10:164–177

    CAS  PubMed  Google Scholar 

  35. Ghahramani P, Rowland-Yeo K, Yeo WW, Jackson PR, Ramsay LE (1998) Protein binding of aspirin and salicylate measured by in vivo ultrafiltration. Clin Pharmacol Therapeut 63:285–295

    CAS  Google Scholar 

Download references

Acknowledgements

This study was sponsored by AstraZeneca R&D Mölndal (Mölndal, Sweden). The staff at AstraZeneca Clinical Pharmacology Unit (Sahlgrenska University Hospital, Göteborg, Sweden) is greatly acknowledged. The study was performed according to Swedish laws and regulations.

Author information

Authors and Affiliations

  1. Experimental Medicine, AstraZeneca R&D Mölndal, 431 83 , Mölndal, Sweden

    Gunnar Fager, Marie Cullberg, Maria Eriksson-Lepkowska, Lars Frison & Ulf G. Eriksson

Authors
  1. Gunnar Fager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Cullberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Eriksson-Lepkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lars Frison
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulf G. Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gunnar Fager.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fager, G., Cullberg, M., Eriksson-Lepkowska, M. et al. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 59, 283–289 (2003). https://doi.org/10.1007/s00228-003-0619-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-003-0619-x

Keywords

Search

Navigation